Argentina Hemophilia Market Size & Outlook, 2024-2030

The hemophilia market in Argentina is expected to reach a projected revenue of US$ 108.6 million by 2030. A compound annual growth rate of 5.4% is expected of Argentina hemophilia market from 2025 to 2030.
Revenue, 2024 (US$M)
$79.0
Forecast, 2030 (US$M)
$108.6
CAGR, 2025 - 2030
5.4%
Report Coverage
Argentina

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Argentina hemophilia market, 2018-2030 (US$M)

Argentina hemophilia market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Argentina hemophilia market highlights

  • The Argentina hemophilia market generated a revenue of USD 79.0 million in 2024 and is expected to reach USD 108.6 million by 2030.
  • The Argentina market is expected to grow at a CAGR of 5.4% from 2025 to 2030.
  • In terms of segment, hemophilia a was the largest revenue generating type in 2024.
  • Hemophilia A is the most lucrative type segment registering the fastest growth during the forecast period.

Hemophilia market data book summary

Market revenue in 2024USD 79.0 million
Market revenue in 2030USD 108.6 million
Growth rate5.4% (CAGR from 2025 to 2030)
Largest segmentHemophilia a
Fastest growing segmentHemophilia A
Historical data2018 - 2023
Base year2024
Forecast period2025 - 2030
Quantitative unitsRevenue in USD million
Market segmentationHemophilia A, Hemophilia B
Key market players worldwideTakeda Pharmaceutical Co Ltd, CSL Ltd, Pfizer Inc, Bayer AG, Biomarin Pharmaceutical Inc, Roche Holding AG ADR, Sanofi SA, Novo Nordisk A/S ADR, Spark Therapeutics, Octapharma AG

Other key industry trends

  • In terms of revenue, Argentina accounted for 0.6% of the global hemophilia market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Latin America, Brazil hemophilia market is projected to lead the regional market in terms of revenue in 2030.
  • Argentina is the fastest growing regional market in Latin America and is projected to reach USD 108.6 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Hemophilia Market Companies

Name Profile # Employees HQ Website
Octapharma AG View profile 10001+ Lachen, Schwyz, Switzerland, Europe http://www.octapharma.com/en.html
Biomarin Pharmaceutical Inc View profile 3401 770 Lindaro Street, San Rafael, CA, United States, 94901 https://www.biomarin.com
Spark Therapeutics View profile 501-1000 Philadelphia, Pennsylvania, United States, North America http://sparktx.com
Takeda Pharmaceutical Co Ltd View profile 49095 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 https://www.takeda.com
CSL Ltd View profile 32000 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 https://www.csl.com
Novo Nordisk A/S ADR View profile 66015 Novo Alle 1, Bagsvaerd, Denmark, 2880 https://www.novonordisk.com
Bayer AG View profile 99723 Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368 https://www.bayer.com
Sanofi SA View profile 87994 46, avenue de la Grande Armée, Paris, France, 75017 https://www.sanofi.com
Pfizer Inc View profile 88000 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 https://www.pfizer.com
Roche Holding AG ADR View profile 103605 Grenzacherstrasse 124, Basel, Switzerland, 4070 https://www.roche.com

Argentina hemophilia market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemophilia market will help companies and investors design strategic landscapes.


Hemophilia a was the largest segment with a revenue share of 77.97% in 2024. Horizon Databook has segmented the Argentina hemophilia market based on hemophilia a, hemophilia b covering the revenue growth of each sub-segment from 2018 to 2030.


  • Argentina Hemophilia Type Outlook (Revenue, USD Million, 2018-2030)
    • Hemophilia A
    • Hemophilia B
    • Others
  • Argentina Hemophilia Treatment Type Outlook (Revenue, USD Million, 2018-2030)
    • On-demand
    • Prophylaxis
  • Argentina Hemophilia Therapy Outlook (Revenue, USD Million, 2018-2030)
    • Factor Replacement Therapy
      • Plasma derived Factor Concentrates
        • Factor VIII
        • Factor IX
      • Recombinant Factor Concentrates
        • Factor VIII
        • Factor VII
        • Factor IX
    • Desmopressin & Fibrin Sealants
    • Gene Therapy & Monoclonal Antibodies
  • Argentina Hemophilia Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
    • Hospital Pharmacies
    • Specialty Pharmacies

Reasons to subscribe to Argentina hemophilia market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Argentina hemophilia market databook

  • Our clientele includes a mix of hemophilia market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Argentina hemophilia market , including forecasts for subscribers. This country databook contains high-level insights into Argentina hemophilia market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Argentina Type - Hemophilia Market size, 2024 - 2030 (US$M)

Argentina Hemophilia Market Outlook Share, 2024 & 2030 (US$M)

Argentina Type - Hemophilia Market size, 2024 - 2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online